IGC Pharma, Inc.: Form 10-Q for the period ended Sep 30, 2017
Filed with the SEC on Nov 17, 2017 and accepted by EDGAR at Nov 17, 2017, 17:03 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2017-07-01 to 2017-09-30 | $235.6k | us-gaap:Revenues |
| Revenue | 6 months2017-04-01 to 2017-09-30 | $288.6k | us-gaap:Revenues |
| Cost of revenue | 3 months2017-07-01 to 2017-09-30 | $163.2k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2017-04-01 to 2017-09-30 | $170.1k | us-gaap:CostOfRevenue |
| Selling, general and administrative | 3 months2017-07-01 to 2017-09-30 | $331.1k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2017-04-01 to 2017-09-30 | $710.0k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2017-07-01 to 2017-09-30 | −$263.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2017-04-01 to 2017-09-30 | −$601.7k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2017-07-01 to 2017-09-30 | $40.8k | us-gaap:InterestExpense |
| Interest expense | 6 months2017-04-01 to 2017-09-30 | $85.4k | us-gaap:InterestExpense |
| Income tax | 3 months2017-07-01 to 2017-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2017-04-01 to 2017-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-07-01 to 2017-09-30 | −$303.8k | us-gaap:NetIncomeLoss |
| Net income | 6 months2017-04-01 to 2017-09-30 | −$678.4k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-07-01 to 2017-09-30 | −$0.01 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2017-04-01 to 2017-09-30 | −$0.02 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-07-01 to 2017-09-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2017-04-01 to 2017-09-30 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2017-07-01 to 2017-09-30 | 29,051,771 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2017-04-01 to 2017-09-30 | 29,051,771 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2017-04-01 to 2017-09-30 | −$627.5k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2017-04-01 to 2017-09-30 | $927 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-09-30 | $597.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-09-30 | $2.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-09-30 | $10.0m | us-gaap:Assets |
| Current liabilities | At period end2017-09-30 | $1.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-09-30 | $3.8m | us-gaap:Liabilities |
| Long-term debt | At period end2017-09-30 | $350.8k | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2017-09-30 | $6.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001185185-17-002428. Last ingested by Listed: Nov 6, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.